. 2018 Nov 27;37(3):391–405. doi: 10.1007/s40273-018-0745-z

Table 1.

Analyses undertaken in the model

gBRCAmut	Non-gBRCAmut
● An analysis comparing niraparib with RS data from the ENGOT-OV16/NOVA study [13] ● A cost-minimisation analysis comparing niraparib with olaparib assuming equal efficacy such that efficacy data from the ENGOT-OV16/NOVA study used for both treatments [13, 19] ● An analysis comparing niraparib with rucaparib considering a naïve side-by-side comparison of results from the ENGOT-OV16/NOVA study for niraparib and the ARIEL3 study for rucaparib [13, 17]	● An analysis comparing niraparib with RS data from the ENGOT-OV16/NOVA study [13] ● An analysis comparing niraparib with olaparib considering a naïve side-by-side comparison of results from the ENGOT-OV16/NOVA study for niraparib and Study 19 for olaparib [13, 15, 16] ● An analysis comparing niraparib with rucaparib considering a naïve side-by-side comparison of results from the ENGOT-OV16/NOVA study for niraparib and the ARIEL3 study for rucaparib [17]

gBRCAmut

Non-gBRCAmut

● An analysis comparing niraparib with RS data from the ENGOT-OV16/NOVA study [13]

● A cost-minimisation analysis comparing niraparib with olaparib assuming equal efficacy such that efficacy data from the ENGOT-OV16/NOVA study used for both treatments [13, 19]

● An analysis comparing niraparib with rucaparib considering a naïve side-by-side comparison of results from the ENGOT-OV16/NOVA study for niraparib and the ARIEL3 study for rucaparib [13, 17]

● An analysis comparing niraparib with RS data from the ENGOT-OV16/NOVA study [13]

● An analysis comparing niraparib with olaparib considering a naïve side-by-side comparison of results from the ENGOT-OV16/NOVA study for niraparib and Study 19 for olaparib [13, 15, 16]

● An analysis comparing niraparib with rucaparib considering a naïve side-by-side comparison of results from the ENGOT-OV16/NOVA study for niraparib and the ARIEL3 study for rucaparib [17]

RS routine surveillance